Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin

Annals of Nuclear Medicine

Volumn 18, Issue 2, 2004, Pages 79-95

  Fukumoto, Mitsutaka ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

201Tl; 99mTc MIBI; 99mTc tetrofosmin; SPECT; Tumor imaging

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; THALLIUM 201; TRACER;

BONE TUMOR; BRAIN INFARCTION; BRAIN INFECTION; BRAIN LYMPHOMA; BRAIN TUMOR; BREAST CANCER; COMPUTER ASSISTED DIAGNOSIS; COMPUTER PROGRAM; COMPUTER SYSTEM; COST; DIAGNOSTIC IMAGING; DRUG MECHANISM; DRUG UPTAKE; EQUIPMENT; HEALTH CARE FACILITY; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; KAPOSI SARCOMA; LUNG CANCER; LYMPHOMA; NUCLEAR MEDICINE; PARATHYROID DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKULL BASE TUMOR; SOFT TISSUE CANCER; SOFT TISSUE TUMOR; THYROID CANCER; TUMOR;

EID: 3042845366     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02985098     Document Type: Review

References (151)

1. + interactions with the cation-selective channel of the sarcoplasmic reticulum. J Membr Biol 1985; 84: 9-23.
2. Rabon EC, Sachs G. Tl interaction with the gastric (K, H)-ATPase. J Membr Biol 1981; 62: 19-27.
3. Bakker-Grunwald T. Movement of thallous ion across the ascites cell membrane. J Membr Biol 1979; 47: 171-183.
4. Hasan M, Ashraf I, Bajpai VK. Electron microscopic study of the effects of Tl poisoning on the rat cerebellum. Forensic Sci 1978; 11: 139-146.
5. Hasan M, Chandra SV, Bajpai VK, Ali SF. Electron microscopic effects of Tl poisoning on the rat hypothalamus and hippocampus: biochemica changes in the cerebrum. Brain Res Bull 1977; 2: 255-261.
6. Deshimaru M, Miyakawa T, Sumiyoshi S, Yasuoka F, Kawano K. Electron microscopic study of experimental thallotoxicosis. Folia Psychiatr Neurol Jpn 1977; 31: 269-275.
7. + increases the permeability of the inner membranes of rat liver mitochondria for monovalent cations. Dokl Biochem Biophys 2001; 378: 145-149.
8. Skulskii IA, Saris NE, Savina MV, Glasunov VV. Uptake of thallous ions by mitochondria is stimulated by nonactin but not by respiration alone. Eur J Biochem 1981; 120: 263-266.
9. Misra UK, Kalita J, Yadav RK, Ranjan P. Tl poisoning: emphasis on early diagnosis and response to haemodialysis. Postgrad Med J 2003; 79: 103-105.
10. Galvan-Arzate S, Santamaria A. Tl toxicity. Toxicol Lett 1998;99:1-13.
11. Hassan IM, Sahweil A, Constantinides C, Mahmoud A, Nair M, Omar YT, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14: 333-340.
12. Biersack HJ, Briele B, Hotze AL, Oehr P, Qian L, Mekkawy MA, et al. The role of nuclear medicine in oncology. Ann Nucl Med 1992; 6: 131-136.
13. Kitapci MT, Tastekin G, Turgut M, Caner B, Kars A, Batista I, et al. Preoperative localization of parathyroid carcinoma using Tc-99m MIBI. Clin Nucl Med 1993; 18: 217-219.
14. Irvin GL 3rd, Prudhomme DL, Deriso GT, Sfakianakis G, Chandarlapaty SK. A new approach to parathyroidectomy. Ann Surg 1994; 219: 579-581.
15. Itoh K, Ishizuka R. Tc-99m-MIBI scintigraphy for recurrent hyperparathyroidism after total parathyroidectomy with autograft. Ann Nucl Med 2003; 17: 315-320.
16. Kiratli PO, Peksoy I, Erbas B, Gedikoglu G, Karabulut N. Technetium-99m pertechnetate uptake in ectopic parathyroid adenoma. Ann Nucl Med 1999; 13: 113-115.
17. Kojima T, Mizumura S, Kumita S, Kumazaki T, Teramoto A. Is technetium-99m-MIBI taken up by the normal pituitary gland? A comparison of normal pituitary glands and pituitary adenomas. Ann Nucl Med 2001; 15: 321-327.
18. 99mTc-MIBI brain spect (functional index ratios) and survival after treatment failure in malignant glioma patients. Anticancer Res 2002; 22: 3081-3085.
19. 201Tl SPET in the detection of recurrent brain tumours after radiation therapy. Nucl Med Commun 2002; 23: 1183-1190.
20. Campeau RJ, Kronemer KA, Sutherland CM. Concordant uptake of Tc-99m sestamibi and Tl-201 in unsuspected breast tumor. Clin Nucl Med 1992; 17: 936-937.
21. m-MIBI: a comparative study with mammography and ultrasonography. Nucl Med Commun 1994; 15: 604-612.
22. Nishiyama Y, Yamamoto Y, Kawasaki Y, Satoh K, Takashima H, Ohkawa M, et al. Accumulation of Tc-99m MIBI in breast lymphoma: comparison with Ga-67 citrate. Ann Nucl Med 1996; 10: 429-432.
23. 201Tl-thallous chloride in tumour cells: role of P-glycoprotein. Q J Nucl Med 1995; 39: 122-128.
24. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998; 77: 353-358.
25. 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 1998; 252: 140-146.
26. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
27. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994; 35: 510-515.
28. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996; 37: 1578-1582.
29. Bae KT, Piwnica-Worms D. Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates. Q J Nucl Med 1997; 41: 101-110.
30. Crankshaw CL, Marmion M, Luker GD, Rao V, Dahlheimer J, Burleigh BD, et al. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein. J Nucl Med 1998; 39: 77-86.
31. Atkins HL, Budinger TF, Lebowitz E, Ansari AN, Greene MW, Fairchild RG, et al. Tl-201 for medical use. Part 3: Human distribution and physical imaging properties. J Nucl Med 1977; 18: 133-140.
32. Kaplan WD, Takvorian T, Morris JH, Rumbaugh CL, Connolly BT, Atkins HL. Tl-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 1987;28:47-52.
33. Waxman AD, Ramanna L, Said J. Tl scintigraphy in lymphoma: relationship to gallium-67. J Nucl Med 1989; 30: 915.
34. +)-activated ATPase of rabbit kidney. Biochim Biophys Acta 1968; 159: 160-166.
35. +-2Cl-cotransport is the central mechanism of ion uptake. Nuklearmedizin 1986; 25: 24-247.
36. 201Tl in tumor bearing animals and inflammatory lesion induced animals. Eur J Nucl Med 1987;12:567-572.
37. Melnick RL, Monti LG, Motzkin SM. Uncoupling of mitochondrial oxidative phosphorylation by Tl. Biochem Biophys Res Commun 1976; 69: 68-73.
38. + in mitochondria. J Membr Biol 1978;44:187-194.
39. Llaurado JG, Madden JA, Smith GA. Effects of dietary magnesium deficiency on Tl-201 kinetics and distribution in rat myocardium: concise communication. J Nucl Med 1983;24:402-407.
40. 201Tl uptake and oxidative metabolism in cultured myocardial cells. Nucl Med Commun 1986; 7: 59-64.
41. 201Tl uptake in transformed and non-transformed cell lines. Nucl Med Commun 1998; 19: 1169-1175.
42. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-1838.
43. Crane P, Laliberte R, Heminway S, Thoolen M, Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993;20:20-25.
44. Backus M, Piwnica-Worms D, Hockett D, Kronauge J, Lieberman M, Ingram P, et al. Microprobe analysis of Tc-MIBI in heart cells: calculation of mitochondrial membrane potential. Am J Physiol 1993; 265: C178-187.
45. Chernoff DM, Strichartz GR, Piwnica-Worms D. Membrane potential determination in large unilamellar vesicles with hexakis (2- methoxyisobutylisonitrile) technetium (I). Biochim Biophys Acta 1993; 22: 1147: 262-266.
46. Mousa SA, Williams SJ, Sands H. Characterization of in vivo chemistry of cations in the heart. J Nucl Med 1987; 28: 1351-1357.
47. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis (2-methoxyisobutylisonitrile)- technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198-2202.
48. Lichtshtein D, Kaback HR, Blume AJ. Use of a nlipophilic cation for determination of membrane potential in neuroblastoma-glioma hybrid cell suspensions. Proc Natl Acad Sci USA 1979; 76: 650-654.
49. Sinusas AJ, Shi Q, Saltzberg MT, Vitols P, Jain D, Wackers FJ, et al. Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia. J Nucl Med 1994; 35: 664-671.
50. Younes A, Songadele JA, Maublant J, Platts E, Pickett R, Veyre A. Mechanism of uptake of technetium-tetrofosmin. II: Uptake into isolated adult rat heart mitochondria. J Nucl Cardiol 1995; 2: 327-333.
51. Koplan BA, Beller GA, Ruiz M, Yang JY, Watson DD, Glover DK. Comparison between Tl-201 and technetium-99m-tetrofosmin uptake with sustained low flow and profound systolic dysfunction. J Nucl Med 1996; 37: 1398-1402.
52. Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m- tetrofosmin, technetium-99m-MIBI and Tl-201 in tumor cell lines. J Nucl Med 1996; 37: 1551-1556.
53. 201Tl in normal and transformed thyroid cell lines. J Nucl Med Allied Sci 1979; 23: 163-166.
54. Platts EA, North TL, Pickett RD, Kelly JD. Mechanism of uptake of technetium-tetrofosmin. I: Uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol 1995; 2: 317-326.
55. Nakamura K, Sammiya T, Hashimoto J, Ishibashi R, Matsumoto K, Kubo A. Comparison of cationic myocardial perfusion agents: characteristics of accumulation in cultured smooth muscle cells. Ann Nucl Med 1996; 10: 375-381.
56. Chen WS, Luker KE, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem Pharmacol 2000; 60: 413-426.
57. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
58. 99mTc-Tetrofosmin uptakes in anaplastic thyroid carcinoma. Eur J Nucl Med 1996; 23: 1142. [Abstract]
59. 99mTc-Q12 into human breast cancer cell lines. Eur J Nucl Med 1996; 23: 1361-1366.
60. 99mTc-Medronate incorporation. Anticancer Res 1999; 19: 255-259.
61. Flamen P, Bossuyt A, Franken PR. Technetium-99m-tetrofosmin in dipyridamole-stress myocardial SPECT imaging: intraindividual comparison with technetium-99m-sestamibi. J Nucl Med 1995; 36: 2009-2015.
62. Widding A, Hesse B, Gadsboll N. Technetium-99m sestamibi and tetrofosmin myocardial single-photon emission tomography: can we use the same reference data base? Eur J Nucl Med 1997; 24: 42-45.
63. Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl)phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30-38.
64. 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group. Circulation 1995; 91: 313-319.
65. Jain D, Wackers FJ, Mattera J, McMahon M, Sinusas AJ, Zaret BL. Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med 1993; 34: 1254-1259.
66. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, et al. Imaging of brain tumor proliferative activity with iodine-131- iododeoxyuridine. J Nucl Med 1994; 35: 1407-1417.
67. Ishibashi M, Taguchi A, Sugita Y, Morita S, Kawamura S, Umezaki N, et al. Tl-201 in brain tumors: Relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. J Nucl Med 1995; 36: 2201-2206.
68. Hayashi T, Kumabe T, Jokura H, Fujihara K, Shiga Y, Watanabe M, et al. Inflammatory demyelinating disease mimicking malignant glioma. J Nucl Med 2003; 44: 565-569.
69. Nadel HR. Tl-201 for oncologic imaging in children. Semin Nucl Med 1993; 23: 243-254.
70. Gorniak RJ, Kramer EL, McMeeking AA, Zagzag D. Tl-201 uptake in cytomegalovirus encephalitis. J Nucl Med 1997; 38: 1386-1388.
71. Lee VW, Antonacci V, Tilak S, Fuller JD, Cooley TP. Intracranial mass lesions: Sequential Tl and gallium scintigraphy in patients with AIDS. Radiology 1999; 211: 507-512.
72. Buchpiguel CA, Alavi JB, Alavi A, Kenyon LC. PET versus SPECT in distinguishing radiation encrosis from tumor recurrence in the brain. J Nucl Med 1995; 36: 159-164.
73. Carvalho PA, Schwartz RB, Alexander E 3rd, Garada BM, Zimmerman RE, Loeffler JS, et al. Detection of recurrent gliomas with quantitative Tl-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 1992; 77: 565-570.
74. Moody EB, Hodes JE, Walsh JW, Thornsberry S. Tl-avid cerebral radiation necrosis. Clin Nucl Med 1994; 19: 611-613.
75. Wijaya J, Bernard E, Roach P, Little N. Moderate Tl-201 chloride uptake in cerebral infarction. Clin Nucl Med 2001; 26:730-731.
76. Arisaka Y, Kodama Y, Ayabe K, Higashi K, Taki S, Oguchi M, et al. Tumor-like accumulation on Tl-201 SPECT in subacute hemorrhagic cerebral infarction. Clin Nucl Med 2001;26:357-358.
77. Tomura N, Hirano H, Kato K, Watarai J, Ito Y, Mineura K. Unexpected accumulation of Tl-201 in cerebral infarction. J Comput Assist Tomogr 1998; 22: 126-129.
78. Bernat I, Toth G, Kovacs L. Tumour-like Tl-201 accumulation in brain infarcts, an unexpected finding on single-photon emission tomography. Eur J Nucl Med 1994; 21: 191-195.
79. Larsson SA, Bergstrand G, Bergstedt H, Berg J, Flygare O, Schnell PO, et al. A special cut-off gamma camera for high-resolution SPECT of the head. J Nucl Med 1984; 25: 1023-1030.
80. Yui N, Togawa T, Kinoshita F, Shimada F, Akiyama Y. Assessment of skull base involvement of nasopharyngeal carcinoma by bone SPECT using three detectors system. KAKU IGAKU (Jpn J Nucl Med) 1992; 29: 37-47.
81. Fukumoto M, Osaki Y, Yoshida D, Ogawa Y, Fujiwara M, Miyazaki N, et al. Dual-isotope SPECT diagnosis of a skull-base metastasis causing isolated unilateral hypoglossal nerve palsy. Ann Nucl Med 1998; 12: 213-216.
82. Fukumoto M, Tsuboi N, Yoshimura N, Kurohara A, Yoshida D, Inomata T, et al. Dual isotope SPECT in malignant Jacod's syndrome. Clin Nucl Med 1998; 23: 437-440.
83. Fukumoto M, Yoshida S, Yoshida D, Kishimoto S. Dual-isotope SPECT of skull-base invasion of head and neck tumors. J Nucl Med 1995; 36: 1741-1746.
84. Waxman AD, Ramanna L, Memsic LD, Foster CE, Silberman AW, Gleischman SH, et al. Tl scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 1993; 34: 18-23.
85. Lee VW, Sax EJ, McAneny DB, Pollack S, Blanchard RA, Beazley RM, et al. A complementary role for Tl-201 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med 1993; 34: 2095-2100.
86. Maurer AH, Caroline DF, Jadali FJ, Manzone TA, Maier WP, Au FC, et al. Limitations of craniocaudal Tl-201 and technetium-99m-sestamibi mammoscintigraphy. J Nucl Med 1995; 36: 1696-1700.
87. Abdel-Dayem HM, Bag R, DiFabrizio L, Aras T, Turoglu HT, Kempf JS, et al. Evaluation of sequential Tl and gallium scans of the chest in AIDS patients. J Nucl Med 1996; 37: 1662-1667.
88. Abdel-Dayem HM. Role of Tl-201 chloride and Tc-99m-sestamibi in tumor imaging. Nucl Med Annual 1994; 181-234. (p. 204)
89. Chin BB, Zukerberg BW, Buchpiguel C, Alavi A. Tl-201 uptake in lung cancer. J Nucl Med 1995; 36: 1514-1519.
90. Higashi K, Nishikawa T, Seki H, Oguchi M, Nambu Y, Ueda Y, et al. Comparison of fluorine-18-FDG PET and Tl-201 SPECT in evaluation of lung cancer. J Nucl Med 2001; 42: 1489-1496.
91. 201Tl SPECT versus [(18F)]FDG PET. J Nucl Med 2001; 42: 1497-1498.
92. Waxman AD, Eller D, Ashook G, Ramanna L, Brachman M, Heifetz L, et al. Comparison of gallium-67-citrate and Tl-201 scintigraphy in peripheral and intrathoracic lymphoma. J Nucl Med 1996; 37: 46-50.
93. Abdel-Dayem HM. Role of Tl-201 chloride and Tc-99m-sestamibi in tumor imaging. Nucl Med Annual 1994; 181-234. (p. 203)
94. Ohtomo K, Terui S, Yokoyama R, Abe H, Terauchi T, Maeda G, et al. Tl-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. J Nucl Med 1996; 37: 1444-1448.
95. Sumiya H, Taki J, Tsuchiya H, Nonomura A, Miyauchi T, Tonami N. Midcourse Tl-201 scinitigraphy to predict tumor response in bone and soft tissue tumors. J Nucl Med 1998; 39: 1600-1604.
96. 201Tl into primary cell cultures from human thyroid tissue in multiplied by TSH. J Nucl Med 2002; 43: 145-152.
97. Abdel-Dayem HM. Role of Tl-201 chloride and Tc-99m-sestamibi in tumor imaging. Nucl Med Annual 1994; 181-234. (p. 212)
98. 201Tl in diagnosis of recurrent or metastatic thyroid cancer. J Nucl Med 2001; 42: 414-419.
99. Brendel AJ, Guyot M, Jeandot R, Lefort G, Manciet G. Tl-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1988; 29: 1515-1520.
100. Unal S, Menda Y, Adalet I, Boztepe H, Ozbey N, Alagol F, et al. Tl-201, Technetium-99m-tetrofosmin and Iodine-131 in detecting differentiated thyroid carcinoma metastases. J Nucl Med 1998; 39: 1897-1902.
101. 201Tl-chloride scintigraphy: a case of prostatic cancer with diffuse bone metastases. KAKU IGAKU (Jpn J Nucl Med) 1995; 32: 1249-1253.
102. Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, et al. Fractional retention of Tc-99m-Sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997; 38: 1348-1351.
103. Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltali E, et al. Clinical validation of the influence of P-glycoprotein on Tc-99m-sestamibi uptake in malignant tumors. J Nucl Med 1997; 38: 1003-1008.
104. 99mTc-MIBI scintigraphy in musculoskeletal tumors. J Nucl Med 2001; 42: 33-37.
105. Haugen BR, Lin EC. Isotope imaging for metastaic thyroid cancer. Endocrinol Metab Clin North Am 2001; 30: 469-492.
106. Caner B, Kitapcl M, Unlu M, Erbengi G, Calikoglu T, Gogus T, et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: A comparative study with technetium-99m-MDP. J Nucl Med 1992; 33: 319-324.
107. Gorlick R, Liao AC, Antonescu C, Huvos AG, Healey JH, Sowers R, et al. Lack of correlation of functional scintigraphy with (99m)technetium- methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma. Clin Cancer Res 2001; 7: 3065-3070.
108. Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, Holman BL, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992; 33: 1516-1522.
109. Kirton A, Kloiber R, Rigel J, Wolff J. Evaluation of pediatric CNS malignancies with (99m)Tc-methoxy-isobutylisonitrile SPECT. J Nucl Med 2002; 43: 1438-1443.
110. m-sestamibi SPET brain imaging for differentiating intracranial lymphoma from non-malignant lesions in AIDS patients. Nucl Med Commun 1998; 19: 47-53.
111. 99mTc-MIBI versus dynamic MRI for non-invasive characterization of breast masses. Eur J Nucl Med 2001; 28: 56-63.
112. Polan RL, Klein BD, Richman RH. Scintimammography in patients with minimal mammographic or clinical findings. Radiographics 2001; 21: 641-655.
113. 99mTc Sestamibi breast imaging for the examination of patients with dense and fatty breasts: multicenter study. Radiology 2001; 222: 149-155.
114. 99mTc-sestamibi for palpable breast lesions. J Nucl Med 2002; 43: 882-888.
115. Piccolo S, Muto P. One step forward. J Nucl Med 2002; 43: 916-917.
116. Waxman AD. The role of Tc-99m-methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997; 27: 40-54.
117. Buscombe JR, Cwikla JB, Holloway B, Hilson AJ. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. J Nucl Med 2001; 42: 3-8.
118. Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000; 24: 274-280.
119. 99mTc-sestamibi scintimammography complementary to conventional mammography for detecting breast cancer in patients with palpable masses? J Nucl Med 2001; 42: 1614-1621.
120. 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med 1999; 29: 16-40.
121. Brem RF, Schoonjans JM, Kieper DA, Majewski S, Goodman S, Civelek C. High-resolution scintimammography: a pilot study. J Nucl Med 2002; 43: 909-915.
122. Khalkhali I, Cutrone J, Mena I, Diggles L, Venegas R, Vargas H, et al. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995; 36: 1784-1789.
123. Villanueva-Meyer J, Leonard MH Jr, Briscoe E, Cesani F, Ali SA, Rhoden S, et al. Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996; 37 (6): 926-930.
124. Khalkhali I, Baum JK, Villanueva-Meyer J, Edell SL, Hanelin LG, Lugo CE, et al. Diagnostic accuracy of 99m-Tc-Sestamibi breast imaging: Multicenter trial results. J Nucl Med 2000; 41: 1973-1979.
125. Prats E, Aisa F, Abos MD, Villavieja L, Garcia-Lopez F, Asenjo MJ, et al. Mammography and Tc-99m-MIBI scintimammography in suspected breast cancer. J Nucl Med 1999; 40: 296-301.
126. Khalkhali I, Cutrone JA, Mena IG, Diggles LE, Venegas RJ, Vargas HI, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
127. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
128. Taillefer R, Robidoux A, Turpin S, Lambert R, Cantin J, Leveille J. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med 1998; 39: 459-464.
129. Tiling R, Sommer H, Pechmann M, Moser R, Kress K, Pfluger T, et al. Comparison of Technetium-99m-sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. J Nucl Med 1997; 38: 58-62.
130. Pisano ED, Parham CA. Digital mammography, sestamibi breast scintigraphy, and positron emission tomography breast imaging. Radiol Clin North Am 2000; 38: 861-869.
131. 99mTc Sestamibi washout in predicting response to locally advanced breast cancer to neoadjuvant chemotherapy. J Nucl Med 2002; 43: 745-751.
132. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med 1992; 33: 1801-1807.
133. Arbab AS, Koizumi K, Hemmi A, Toyama K, Arai T, Yoshitomi T, et al. Tc-99m-MIBI scintigraphy for detecting parathyroid adenoma and hyperplasia. Ann Nucl Med 1997; 11: 45-49.
134. Carpentier A, Jeannotte S, Verreault J, Lefebvre B, Bisson G, Mongeau CJ, et al. Preoperative localization of parathyroid lesions in hyperparathyroidism: relationship between technetium-99m-MIBI uptake and oxyphil cell content. J Nucl Med 1998; 39: 1441-1444.
135. Miyamoto S, Kasagi K, Misaki T, Alam MS, Konishi J. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 1998; 38: 352-356.
136. 131I ablative therapy. J Nucl Med 1999; 40: 1434-1440.
137. Balon HR, Fink-Bennet TD, Stoffer SS. Technetium-99m-sestamibi uptake by recurrent hurthle cell carcinoma of the thyroid. J Nucl Med 1992; 33: 1393-1395.
138. O'Driscoll CM, Baker F, Casey MJ, Duffy GJ. Localization of recurrent medullary thyroid carcinoma with technetium-99m-methoxyisobutylnitrile scintigraphy: A case report. J Nucl Med 1991; 32: 2281-2283.
139. 18F-fluorodeoxyglucose. J Neurooncol 2000; 46: 63-70.
140. Soricelli A, Cuocolo A, Varrone A, Discepolo A, Tedeschi E, Mainenti PP, et al. Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: comparison with Tl-201 imaging. J Nucl Med 1998; 39: 802-806.
141. Perek N, Prevot N, Koumanov F, Frere D, Sabido O, Beauchesne P, et al. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines. Nucl Med Biol 2000; 27: 299-307.
142. Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid cancer. J Nucl Med 1997; 38: 348-352.
143. Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1998; 39: 870-875.
144. 99mTc-tetrofosmin chest imaging. J Nucl Med 2001; 42: 17-20.
145. Fukumoto M, et al. Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: technetium 99m-tetrofosmin and Tl-201 dual single photon emission computed tomography study. Cancer 1999;86:1470-1479.
146. Ishibashi M, Nishida H, Kumabe T, Morita S, Matoba F, Nomura G, et al. Tc-99m tetrofosmin. A new diagnostic tracer for parathyroid imaging. Clin Nucl Med 1995; 20: 902-905.
147. Mansi L, Rambaldi PF, Marino G, Pecori B, Del Vecchio E. Kinetics of Tc-99m sestamibi and Tc-99m tetrofosmin in a case of parathyroid adenoma. Clin Nucl Med 1996; 21: 700-703.
148. Fjeld JG, Erichsen K, Pfeffer PF, Clausen OP, Rootwelt K. Technetium-99m-tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi. J Nucl Med 1997; 38: 831-834.
149. Takeuchi N, Fukumoto M, Nishioka A, Akagi N, Murata Y, Takeuchi S, et al. Scintigraphic prediction of response to chemotherapy in patients with breast cancer: Technetium 99m-tetrofosmin and Tl-201 dual single photon emission computed tomography. Int J Oncol 2002; 20: 53-58.
150. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Kao CH. Technetium-99m tetrofosmin mammoscintigraphy findings related to the expression of P-glycoprotein mediated multidrug resistance. Anticancer Res 2000; 20: 1467-1470.
151. Fuster D, Vinolas N, Mallafre C, Pavia J, Martin F, Pons F. Tetrofosmin as predictors of tumour response. Q J Nucl Med 2003; 47: 58-62.